📊 BBLGW Key Takeaways
Investment Thesis
Bone Biologics is a pre-revenue or near-complete revenue collapse company with zero gross profit, massive operating losses, and severely negative cash flow generation. The company is rapidly burning through its cash reserves ($5.3M) at approximately $2.7M annually with no clear path to profitability or sustainable operations.
BBLGW Strengths
- Strong liquidity position with $5.3M cash and 13.85x current ratio
- Minimal debt burden with zero long-term debt provides financial flexibility
- Positive stockholders equity of $5.4M and conservative capital structure
BBLGW Risks
- Operating cash flow of -$2.7M annually indicates cash will deplete in ~2 years at current burn rate
- Complete revenue collapse (100% YoY decline) suggests business model failure or operational discontinuation
- Negative operating margin of -1,268,604% demonstrates inability to achieve profitability with current revenue base
- Dilution risk evident from worsening EPS despite net income improvement, indicating significant equity issuance
- No gross profit generation suggests fundamental product viability or market demand issues
Key Metrics to Watch
- Operating cash flow trend and cash runway remaining
- Revenue stabilization or return to meaningful sales levels
- Gross margin recovery once revenue reaches viable levels
- Additional equity dilution and insider activity patterns
BBLGW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 13.85x current ratio provides a solid financial cushion.
BBLGW Profitability Ratios
BBLGW vs Default Sector
How Bone Biologics Corp compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BBLGW Balance Sheet & Liquidity
BBLGW 5-Year Financial Trend
5-Year Trend Summary: Bone Biologics Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-28.96 indicates the company is currently unprofitable.
BBLGW Growth Metrics (YoY)
BBLGW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2021 | $1.1B | -$380.0K | N/A |
| Q1 2021 | $1.1B | -$431.7K | N/A |
| Q3 2020 | $1.1B | -$380.0K | N/A |
| Q2 2020 | $1.1B | -$380.0K | N/A |
| Q1 2020 | $1.1B | -$596.9K | N/A |
| Q1 2019 | $1.1B | -$1.4M | N/A |
| Q3 2018 | $1.1B | -$241.7K | N/A |
| Q2 2018 | $1.1B | $1.0M | $0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BBLGW Capital Allocation
BBLGW SEC Filings
Access official SEC EDGAR filings for Bone Biologics Corp (CIK: 0001419554)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BBLGW
What is the AI rating for BBLGW?
Bone Biologics Corp (BBLGW) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BBLGW's key strengths?
Strong liquidity position with $5.3M cash and 13.85x current ratio. Minimal debt burden with zero long-term debt provides financial flexibility.
What are the risks of investing in BBLGW?
Operating cash flow of -$2.7M annually indicates cash will deplete in ~2 years at current burn rate. Complete revenue collapse (100% YoY decline) suggests business model failure or operational discontinuation.
What is BBLGW's revenue and growth?
Bone Biologics Corp reported revenue of $255.0.
Does BBLGW pay dividends?
Bone Biologics Corp does not currently pay dividends.
Where can I find BBLGW SEC filings?
Official SEC filings for Bone Biologics Corp (CIK: 0001419554) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BBLGW's EPS?
Bone Biologics Corp has a diluted EPS of $-2.65.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.